A global action agenda for turning the tide on fatty liver disease

Jeffrey V. Lazarus*, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Quentin M. Anstee, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Graciela E. Castro-Narro, Helena Cortez-Pinto, Kenneth Cusi, Nikos Dedes, Ajay DusejaSven M. Francque, Amalia Gastaldelli, Hannes Hagström, Terry T.K. Huang, Dana Ivancovsky Wajcman, Achim Kautz, Christopher J. Kopka, Aleksander Krag, Philip N. Newsome, Mary E. Rinella, Diana Romero, Shiv Kumar Sarin, Marcelo Silva, C. Wendy Spearman, Norah A. Terrault, Emmanuel A. Tsochatzis, Luca Valenti, Marcela Villota-Rivas, Shira Zelber-Sagi, Jörn M. Schattenberg, Vincent Wai Sun Wong, Zobair M. Younossi, Fredrik Aberg, Leon A. Adams, Khalid Al-Naamani, Reda M. Albadawy, Zinaida Alexa, Michael Allison, Faisal Abdullatif Alnaser, Khalid Alswat, Ger Koek, Jean Muris, Healthy Livers, Healthy Lives Collaborators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
Original languageEnglish
Number of pages22
JournalHepatology
DOIs
Publication statusE-pub ahead of print - Aug 2023

Cite this